Adimab, LLC - Aug 10, 2021 Form 4 Insider Report for Adagio Therapeutics, Inc. (IVVD)

Role: 10%+ Owner
Signature: /s/ Philip Chase, General Counsel
Stock symbol: IVVD
Transactions as of: Aug 10, 2021
Transactions value $: $0
Form type: 4
Date filed: 8/12/2021, 09:22 PM
Previous filing: Aug 5, 2021
Next filing: Apr 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IVVD	Common Stock	Conversion of derivative security		+25.9M	+1302.61%		27.8M	Aug 10, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IVVD	Series A Preferred Stock	Conversion of derivative security	$0	-5M	-100%	$0.00^*	0	Aug 10, 2021	Common Stock	25M		Direct	F1
transaction	IVVD	Series B Preferred Stock	Conversion of derivative security	$0	-44.1K	-100%	$0.00^*	0	Aug 10, 2021	Common Stock	220K		Direct	F1
transaction	IVVD	Series C Preferred Stock	Conversion of derivative security	$0	-128K	-100%	$0.00^*	0	Aug 10, 2021	Common Stock	640K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.